Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
christensenella minuta
- Development stage
- Unknown
- Lead developer
- YSOPIA Bioscience
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral, Rectal
01
Overview
*Christensenella minuta* is a species of gut bacteria being developed as a next-generation probiotic or live biotherapeutic product (LBP). [4] This Gram-negative, anaerobic bacterium is strongly associated with leanness and metabolic health in humans. [4, 5] It is under investigation for its therapeutic potential in a range of conditions including obesity, metabolic diseases, inflammatory bowel disease (IBD), liver fibrosis, and polycystic ovary syndrome (PCOS). One specific product, coded Xla1, has completed a Phase 1 clinical trial for obesity and metabolic disorders. [3, 8] The proposed mechanisms of action are multi-faceted and include the production of beneficial short-chain fatty acids (SCFAs) like butyrate, modulation of the host's immune system by inhibiting pathways such as NF-κB, enhancement of gut barrier integrity, and regulation of metabolic pathways through the gut-liver and gut-brain axes. [4, 12]
Beyond the preview
Go deeper on christensenella minuta.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on christensenella minuta.